New mechanisms-based therapies in acute ischaemic stroke

Guido Stoll,Michael K Schuhmann,Alexander M Kollikowski,Mirko Pham

DOI: https://doi.org/10.1093/eurheartj/ehad865

IF: 39.3

2024-01-10

European Heart Journal

Abstract:Rapid reconstitution of blood flow by recanalization has been the primary therapeutic strategy in acute ischaemic stroke (AIS) after large vessel occlusion (LVO). In recent years, thrombolysis and endovascular mechanical thrombectomy (EVT), alone or combined, have seen ongoing refinement, including the extension of treatment time windows. Despite nearly achieving a 100% technical success rate in EVT for full recanalization (referred to as eTICI ≥ 2b), the individual prognosis of LVO stroke remains poor, with only about 35%–55% favourable outcome and 14%–28% mortality at 3 months. 1 Mortality reaches 36%–40% when infarcts have progressed to consume large brain volumes before EVT recanalization is performed. 2 These data show that recanalization is a pre-requisite for a better functional outcome, but individual prognosis remains poor for a large group of treated patients. This calls for add-on treatments. Experimental stroke models and observational clinical studies strongly indicate that progressive brain infarction throughout the delay from onset to treatment (during occlusion) and beyond successful recanalization [ischaemia/reperfusion (I/R) injury] mostly account for poor outcome. Novel mechanisms-based pharmacological approaches to delay or limit progressive brain infarction, such as classical neuroprotection 3 and targeting stroke-induced inflammation, 4 are currently in clinical development.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

This paper attempts to solve several key problems in the treatment of acute ischaemic stroke (AIS):

1. **Although significant progress has been made in revascularization techniques (such as mechanical thrombectomy, EVT), the overall prognosis of patients remains poor**:
- Although the mechanical thrombectomy (EVT) can achieve almost 100% success rate technically, only about 35% - 55% of patients can achieve good functional recovery within 3 months after treatment, and the mortality rate is still as high as 14% - 28%.
- When the infarcted area extends to a large - volume area of the brain, the mortality rate is even higher, reaching 36% - 40%.

2. **New mechanism - based treatment methods need to be developed to improve the prognosis of patients**:
- Studies have shown that the time delay from the onset of the disease to treatment and reperfusion injury (Ischaemia/Reperfusion, I/R) are the main causes of poor prognosis.
- Therefore, new drug treatment methods need to be developed to delay or limit the progressive infarction of brain tissue, thereby improving the treatment effect.

3. **Explore new strategies for neuroprotective agents and anti - inflammatory treatments**:
- **Neuroprotective agents**: For example, the PSD - 95 inhibitor Nerinetide has been proven to reduce ischaemic brain damage in animal experiments. The results of clinical trials (such as FRONTIER and ESCAPE - NEXT) show that early application of Nerinetide may help to "freeze" the penumbra, thereby delaying the occurrence of cerebral infarction.
- **Anti - inflammatory treatment**: Acute ischaemic stroke triggers a strong inflammatory response, especially the activation of platelets and T - cells. Research is exploring treatment methods targeting these inflammatory pathways, such as using FTY720 (Fingolimod) and antibodies against GPVI (such as Glenzocimab).

4. **Optimize the treatment time window**:
- Through early intervention (such as random grouping and drug administration outside the hospital), neuroprotective agents can be applied earlier, thereby improving the treatment effect.

In conclusion, this paper emphasizes the importance of developing new mechanism - based treatment methods on the basis of existing revascularization techniques to further improve the prognosis of patients with acute ischaemic stroke.